The Mark Cuban Cost Plus Drug Company has entered into a new partnership with the aim of making obesity medications affordable for self-insured employers.
Under the collaboration, cardiometabolic company 9amHealth will “leverage” obesity medications applied orally from Cost Plus Drugs to help treat conditions like diabetes and hypertension, according to a company announcement. This includes GLP-1-branded drugs.
“At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with clinical leaders in obesity like 9amHealth, we are dedicated to providing affordable and accessible healthcare solutions for patients with cardiometabolic conditions,” said Cost Plus Drug Company CEO Alex Oshmyansky, M.D., Ph.D., in a statement.
Member enrollees will also have access to 9amHealth’s team of providers including physicians, endocrinologists and cardiometabolic specialists. Home lab testing and delivery services will be available as well.
GLP-1 drugs will be offered at fixed monthly costs with variable cost share through 9amHealth’s manufacturer partnerships.
Cost Plus Drugs, led by television personality and businessman Mark Cuban, has become a household name for the access it gives customers to discounted generic drugs.
The two companies say the relationship is a way to save employers and pharmacy benefit managers costs for medications.
“Our collaboration gives employers a way to provide expert medical management of obesity, without the massive price tag,” said Paul Geevarghese, chief operating officer and co-founder of 9amHealth, in a statement.
Cuban’s company recently developed partnerships with health systems and announced plans to manufacture its own drugs.
9amHealth, a Fierce Healthcare Fierce 15 honoree in 2024, was backed by Cigna to the tune of $9.5 million in early 2024.
Publisher: Source link
